Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
A Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15±3.
1. A method of treating a subject suffering from traveler's diarrhea comprising:
selecting a subject in need of treatment of traveler's diarrhea;
administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of Rifaximin in an α/β polymorphic mixture of 85/15±3 in an amount sufficient to treat the traveler's diarrhea, wherein the Rifaximin α/β polymorphic mixture is characterized by an X-Ray spectrum with characteristic 2theta values at: 5.32, 5.78, 6.50, 7.24, 7.82, 8.80, 10.50, 11.02, 11.58, 13.08, 14.42, 17.32, 17.68, 18.58, 19.52, 21.04, 21.60, and 21.92.
2. The method of claim 1 , wherein the pharmaceutical composition is a solid pharmaceutical composition.
3. The method of claim 2 , wherein the pharmaceutical composition is a film coated tablet.
4. The method of claim 1 , wherein the pharmaceutical composition comprises 550 mg of Rifaximin α/β polymorphic mixture of 85/15±3.
5. The method of claim 1 , wherein the pharmaceutical composition further comprises excipients.
6. The method of claim 5 , wherein the excipients comprise cellulose microcrystalline, sodium starch glycolate, glyceryl palmitostearate, hydrated silicon dioxide, and talc.
7. The method of claim 6 , wherein the pharmaceutical composition further comprises polyvinyl alcohol, polyethylene glycol, titanium dioxide, and red iron oxide.
8. The method of claim 7 , wherein the pharmaceutical composition has a hardness of 18.49±1.30 Kp, a thickness of about 5.48±0.06 mm, a friability of about 0.058%, and a disintegration in purified water at 37° C. of about 1′20″.
9. A method of treating a subject suffering from hepatic encephalopathy comprising:
selecting a subject in need of treatment of hepatic encephalopathy;
administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of Rifaximin in an α/β polymorphic mixture of 85/15±3 in an amount sufficient to treat the hepatic encephalopathy, wherein the Rifaximin α/β polymorphic mixture is characterized by an X-Ray spectrum with characteristic 2theta values at: 5.32, 5.78, 6.50, 7.24, 7.82, 8.80, 10.50, 11.02, 11.58, 13.08, 14.42, 17.32, 17.68, 18.58, 19.52, 21.04, 21.60, and 21.92.
10. The method of claim 9 , wherein the pharmaceutical composition is a solid pharmaceutical composition.
11. The method of claim 10 , wherein the pharmaceutical composition is a film coated tablet.
12. The method of claim 9 , wherein the pharmaceutical composition comprises 550 mg of Rifaximin α/β polymorphic mixture of 85/15±3.
13. The method of claim 9 , wherein the pharmaceutical composition further comprises excipients.
14. The method of claim 13 , wherein the excipients comprise cellulose microcrystalline, sodium starch glycolate, glyceryl palmitostearate, hydrated silicon dioxide, and talc.
15. The method of claim 14 , wherein the pharmaceutical composition further comprises polyvinyl alcohol, polyethylene glycol, titanium dioxide, and red iron oxide.
16. The method of claim 15 , wherein the pharmaceutical composition has a hardness of 18.49±1.30 Kp, a thickness of about 5.48±0.06 mm, a friability of about 0.058%, and a disintegration in purified water at 37° C. of about 1′20″.